Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hyperlipoproteinemias

  Free Subscription


Articles published in Curr Opin Lipidol

Retrieve available abstracts of 41 articles:
HTML format



Single Articles


    February 2024
  1. CHAN DC, Watts GF
    ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Curr Opin Lipidol. 2024 Feb 20. doi: 10.1097/MOL.0000000000000920.
    PubMed     Abstract available


  2. VAN DEN BOSCH SE, Hutten BA, Corpeleijn WE, Kusters DM, et al
    Familial hypercholesterolemia in children and the importance of early treatment.
    Curr Opin Lipidol. 2024 Feb 15. doi: 10.1097/MOL.0000000000000926.
    PubMed     Abstract available


  3. ZHANG Y, de Ferranti SD, Moran AE
    Genetic testing for familial hypercholesterolemia.
    Curr Opin Lipidol. 2024 Feb 1. doi: 10.1097/MOL.0000000000000925.
    PubMed     Abstract available


    December 2023
  4. PERERA SD, Hegele RA
    Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Dec 21. doi: 10.1097/MOL.0000000000000916.
    PubMed     Abstract available


  5. ROMERO-JIMENEZ MJ, Mansilla-Rodriguez ME, Gutierrez-Cortizo EN
    Predictors of cardiovascular risk in familial hypercholesterolemia.
    Curr Opin Lipidol. 2023;34:272-277.
    PubMed     Abstract available


  6. GILLARD BK, Rosales C, Gotto AM Jr, Pownall HJ, et al
    The pathophysiology of excess plasma-free cholesterol.
    Curr Opin Lipidol. 2023;34:278-286.
    PubMed     Abstract available


  7. KARALIS DG
    Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:252-258.
    PubMed     Abstract available


    November 2023
  8. ROY G, Drouin-Chartier JP
    Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
    Curr Opin Lipidol. 2023 Nov 2. doi: 10.1097/MOL.0000000000000908.
    PubMed     Abstract available


    August 2023
  9. CHOUDHARI P, Patni N
    Updates in the management of pediatric dyslipidemia.
    Curr Opin Lipidol. 2023;34:156-161.
    PubMed     Abstract available


    June 2023
  10. GANDA OP
    Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:105-113.
    PubMed     Abstract available


  11. WADSTROM BN, Pedersen KM, Wulff AB, Nordestgaard BG, et al
    Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:96-104.
    PubMed     Abstract available


    April 2023
  12. CLARKE SL
    Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
    Curr Opin Lipidol. 2023;34:52-58.
    PubMed     Abstract available


    March 2023
  13. VUORIO A, Raal F, Kovanen PT
    Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19.
    Curr Opin Lipidol. 2023 Mar 10. doi: 10.1097/MOL.0000000000000876.
    PubMed     Abstract available


    February 2023
  14. HANG SMT, Hegele RA, Berberich AJ
    Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Feb 2. doi: 10.1097/MOL.0000000000000866.
    PubMed     Abstract available


    January 2023
  15. REIJMAN MD, Defesche JC, Wiegman A
    Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2023 Jan 18. doi: 10.1097/MOL.0000000000000863.
    PubMed     Abstract available


    December 2022
  16. DRON JS
    The clinical utility of polygenic risk scores for combined hyperlipidemia.
    Curr Opin Lipidol. 2022 Dec 28. doi: 10.1097/MOL.0000000000000865.
    PubMed     Abstract available


  17. WEI T, Cho L
    Recent lipoprotein(a) trials.
    Curr Opin Lipidol. 2022;33:301-308.
    PubMed     Abstract available


  18. TRAMONTANO D, Bini S, D'Erasmo L, Arca M, et al
    Recent Apolipoprotein CIII trials.
    Curr Opin Lipidol. 2022;33:309-318.
    PubMed     Abstract available


    October 2022
  19. TROMP TR, Cuchel M
    New algorithms for treating homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2022 Oct 5. pii: 00041433-990000000-00014.
    PubMed     Abstract available


  20. SCIPIONE CA, Cybulsky MI
    Early atherogenesis: new insights from new approaches.
    Curr Opin Lipidol. 2022;33:271-276.
    PubMed     Abstract available


    August 2022
  21. MARTINS J, Rossouw HM, Pillay TS
    How should low-density lipoprotein cholesterol be calculated in 2022?
    Curr Opin Lipidol. 2022;33:237-256.
    PubMed     Abstract available


    July 2022
  22. LEREN TP, Bogsrud MP
    Cascade screening for familial hypercholesterolemia should be organized at a national level.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00004.
    PubMed     Abstract available


  23. DURRINGTON PN, Bashir B, Bhatnagar D, Soran H, et al
    Lipoprotein (a) in familial hypercholesterolaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00005.
    PubMed     Abstract available


  24. PAQUETTE M, Bernard S, Baass A
    Diagnosis of remnant hyperlipidaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00002.
    PubMed     Abstract available


    December 2021
  25. ANTONIAZI L, Arroyo-Olivares R, Mata P, Santos RD, et al
    Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Dec 13. pii: 00041433-900000000-99240.
    PubMed     Abstract available


  26. MEDEIROS AM, Bourbon M
    Polygenic contribution for familial hypercholesterolemia (FH).
    Curr Opin Lipidol. 2021;32:392-395.
    PubMed     Abstract available


  27. MATA P, Alonso R, Perez de Isla L, Badimon L, et al
    Dyslipidemia and aortic valve disease.
    Curr Opin Lipidol. 2021;32:349-354.
    PubMed     Abstract available


    October 2021
  28. GILL PK, Hegele RA
    Familial combined hyperlipidemia is a polygenic trait.
    Curr Opin Lipidol. 2021 Oct 22. pii: 00041433-900000000-99252.
    PubMed     Abstract available


  29. MCINTOSH CS, Watts GF, Wilton SD, Aung-Htut MT, et al
    Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.
    Curr Opin Lipidol. 2021 Oct 15. pii: 00041433-900000000-99253.
    PubMed     Abstract available


  30. GRAHAM DF, Raal FJ
    Management of familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2021 Oct 6. pii: 00041433-900000000-99256.
    PubMed     Abstract available


    September 2021
  31. THOMPSON GR
    Use of apheresis in the age of new therapies for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2021 Sep 22. pii: 00041433-900000000-99259.
    PubMed     Abstract available


    August 2021
  32. IQBAL Z, Bashir B, Ferdousi M, Kalteniece A, et al
    Lipids and peripheral neuropathy.
    Curr Opin Lipidol. 2021;32:249-257.
    PubMed     Abstract available


  33. DRON JS, Hegele RA
    Editorial: Discussing polygenic risk with lipid clinic patients.
    Curr Opin Lipidol. 2021;32:273-275.
    PubMed    


    April 2021
  34. MOHAMED F, Botha TC, Raal FJ
    Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Curr Opin Lipidol. 2021 Apr 20. pii: 00041433-900000000-99277.
    PubMed     Abstract available


  35. PULIPATI VP, Davidson MH
    The clinical black, white, and gray lessons.
    Curr Opin Lipidol. 2021;32:151-156.
    PubMed     Abstract available


  36. FONG V, Patel SB
    Recent advances in ABCG5 and ABCG8 variants.
    Curr Opin Lipidol. 2021;32:117-122.
    PubMed     Abstract available


    February 2021
  37. CHORA JR, Bourbon M
    Pharmacogenomics of statins and familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Feb 10. pii: 00041433-900000000-99283.
    PubMed     Abstract available


  38. BALVERS M, van den Born BH, Levin E, Nieuwdorp M, et al
    Impact drugs targeting cardiometabolic risk on the gut microbiota.
    Curr Opin Lipidol. 2021;32:38-54.
    PubMed     Abstract available


    October 2020
  39. YEANG C, Willeit P, Tsimikas S
    The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000713.
    PubMed     Abstract available


  40. IBRAHIM S, Reeskamp LF, Stroes ESG, Watts GF, et al
    Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000714.
    PubMed     Abstract available


    September 2020
  41. WOLSKA A, Yang ZH, Remaley AT
    Hypertriglyceridemia: new approaches in management and treatment.
    Curr Opin Lipidol. 2020 Sep 29. doi: 10.1097/MOL.0000000000000710.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.